Clinical trial · Observational
Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma
Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Marginal Zone Lymphoma | Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lisocabtagene maraleucel | Biological | Lisocabtagene Maraleucel | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Lisocabtagene maraleucel
- description
- Adult participants with relapsed or refractory marginal zone lymphoma (R/R MZL) treated with lisocabtagene maraleucel
- interventionNames
- Biological: lisocabtagene maraleucel
Primary outcomes (1)
- measure
- Incidence and severity of selected adverse events after lisocabtagene maraleucel infusion
- timeFrame
- Up to 15 years
- description
- Selected adverse events include: * secondary malignancies * cytokine release syndrome (CRS) Grade ≥ 3 * neurotoxicity Grade ≥ 3 * prolonged cytopenias * pregnancy outcome * treatment-emergent adverse events including: hypogammaglobulinemia, tumor lysis syndrome Grade ≥ 3, serious infections requiring treatment, organ toxicities Grade ≥ 3, hemophagocytic lymphohistiocytosis/macrophage activation syndrome-like toxicities, aggravated graft-versus-host disease, and other toxicities occurring after lisocabtagene maraleucel infusion.
Secondary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Participants who meet the following eligibility criteria will be selected from the registry: * Participants of 18 years of age or older at the time of infusion * Participants with a diagnosis of relapsed or refractory marginal zone lymphoma (R/R MZL) * Participants have received at least two prior lines of systemic therapy * Participants have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel: * used for the treatment of R/R MZL, * within the FDA-approved indication and dosage per the United States prescribing information and * product specifications approved for commercial release in the USA. * Participants have consented to share their data with the registry and the Sponsor. Exclusion Criteria: Participants who meet the following exclusion criterion will not be eligible for selection from the registry: • Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion.
References
Publications (0)
Data not yet available